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OBJECTIVE: The aim of the study was to evaluate the cost-
effectiveness of peginterferon alfa-2a (40KD) for the treatment
of patients with HBeAg-negative chronic hepatitis B in Poland.
The analysis compared two strategies: peginterferon alfa-2a
(40KD) vs. lamivudine for 48 weeks (short-term analysis) or
peginterferon alfa-2a (40KD) for 48 weeks vs. lamivudine for 4
years (long-term analysis). METHODS: The analysis was per-
formed from the Polish payer perspective using a state-transition
Markov model. Quality-adjusted life years (QALYs) was
adopted as a measure of effectiveness. Efﬁcacy with peginter-
feron alfa-2a (40KD) and lamivudine after 48 weeks of treat-
ment was obtained from a randomized controlled trial
(Marcellin et al. NEJM 2004;351(12):32–43). Long-term
lamivudine efﬁcacy, health state transition probabilities and
utility estimates were obtained from the published literature.
Direct medical costs, i.e. cost of drugs and procedures in the
treatment of hepatitis B and its complications (cirrhosis, hepa-
tocellular carcinoma, liver transplantation) were obtained from
Polish sources. Costs and beneﬁts were discounted at a 3%
annual rate. RESULTS: Peginterferon alfa-2a 40(KD) vs. lamivu-
dine for 48 weeks (short-term analysis) increased QALYs by
0,89. The mean treatment cost in the short-term analysis was
17,743 € (1€ = 4.035 PLN) and 12,522 € per patients for pegin-
terferon alfa-2a and lamivudine, respectively. The incremental
cost-effectiveness ratio (ICER) was 9316 €/QALY gained. In the
long-term analysis, peginterferon alfa-2a (40KD) increased
QALYs by 0,75. The mean cost of treatment was 17 €398 for
peginterferon alfa-2a (40KD) and €13,890 for lamivudine per
patient. The incremental cost-effectiveness ratio (ICER) was
€7643 per QALY gained. CONCLUSIONS: The ICER for pegin-
terferon alfa-2a evaluated in the short-term analysis as well as
in the long-term analysis did not exceed €14,870 (cost of one
year dialysis in Poland). Thus, the procedure appears to be cost-
effective in Poland.
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OBJECTIVES: Primary (ﬁrst and subsequent cycles) prophylaxis
with ﬁlgrastim or pegﬁlgrastim has been recommended in 2006
clinical guidelines when the risk of febrile neutropenia (FN) is
about 20%. Recent studies reported signiﬁcantly greater reduc-
tion of FN with pegﬁlgrastim. In clinical practice, ﬁlgrastim has
often been used for fewer than the recommended 11 days (e.g.,
5–6 days), which has been shown to compromise the clinical out-
comes. The study purpose was to evaluate the cost-effectiveness
of pegﬁlgrastim vs. ﬁlgrastim (11- or 6-day) primary prophylaxis
in women with breast cancer (stage I-III) receiving chemother-
apy with moderate to high FN risk in Germany. METHODS: We
constructed a decision-analytic model from a health care payer’s
perspective. Costs included drugs, drug administration, FN-
related hospitalizations and subsequent costs, and were based on
Rote Liste (list price) and DRG Tariff. Effectiveness was mea-
sured as FN avoided and life-year-gained (LYG). FN risk (varied
by days of ﬁlgrastim), FN case-fatality, relative dose intensity
(RDI), and the impact of RDI on survival were based on a com-
prehensive literature review and expert panel validation. Breast
cancer mortality and all-cause mortality were from ofﬁcial sta-
tistics. Sensitivity analyses were conducted on key variables.
RESULTS: Pegﬁlgrastim use avoided more FN events, produced
greater LYG and was less expensive than 11-day ﬁlgrastim. Com-
pared with 6-day ﬁlgrastim, pegﬁlgrastim avoided 10.5 absolute
percentage point of FN (17.5% vs. 7%) at a modest cost increase
(€1306); the incremental cost-effectiveness ratio (ICER) was
€12,429 per FN avoided. The average life expectancy was 15.99
years with pegﬁlgrastim and 15.88 years with ﬁlgrastim, yield-
ing an ICER of €11,972/LYG. Age of diagnosis and cancer stage
had minimal impact on the results. Drug costs and FN risk has
moderate inﬂuence on model results. CONCLUSIONS: In
Germany, pegﬁlgrastim appeared to dominate 11-day ﬁlgrastim
and to be cost-effective within normal thresholds compared with
6-days ﬁlgrastim per cycle.
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OBJECTIVE: To model the cost-effectiveness entecavir (ETV) 
in treating chronic hepatitis B (CHB) in Sweden. METHODS:
Design: A modiﬁed decision tree model was developed to
compare two hypothetical cohorts of CHB patients undergoing
therapy with antiviral agents. Based on patient viral load, the
model estimates the progression to compensated cirrhosis (CC),
decompensated cirrhosis (DC) and hepatocellular carcinoma
(HCC). The multivariate-adjusted risk-predicting models were
developed based on the R.E.V.E.A.L.-HBV Study cohort with
42,115 person-years of follow-up. Perspective: Health care
payer. Patient populations: 1. Nucleoside-naïve patients: 0.5 mg
ETV vs. 100 mg lamivudine (LVD) with adefovir (ADV) admin-
istered as salvage therapy in case of resistance to LVD. 2. LVD-
refractory patients: 1.0 mg ETV vs. 10 mg ADV. Effectiveness:
Efﬁcacy data were used from published clinical trial results. Life-
expectancy was estimated by the DEALE method, using Swedish
life tables. Utility values were obtained by standard gamble in a
CHB health-utility study. Costs: 10-year treatment costs were
estimated using drug acquisition costs published by the LFN.
Costs of CC, DC, and HCC are from a Swedish costing study.
Discounting: Both costs and outcomes were discounted at 3%
annually. Sensitivity analyses were performed to various para-
meters. RESULTS: ETV therapy in nucleoside-naïve patients is a
dominant treatment strategy compared to LVD therapy with
ADV salvage. Cost savings of SEK 8,121,199/SEK 1,1902,137,
QALYs gained 85.70/19.17 for HBeAg-positive/HBeAg–negative
patients, respectively. Treatment with ETV is a dominant treat-
ment strategy compared to ADV in LVD-refractory patients.
Cost savings: SEK 3,612,483, QALYs gained 38.67. Across
patient populations and comparators, ETV was associated with
lower projections of liver-related events, a lower mortality rate
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and higher QALYs. The results were robust to sensitivity analy-
ses. CONCLUSIONS: ETV is a dominant treatment option
across all populations in the treatment of patients with CHB,
compared to LVD and ADV. The results clearly suggest that sup-
pressing VL is economically attractive.
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OBJECTIVES: The risk of HIV, HBV and HCV transmission by
blood transfusion in sub Saharan Africa is (very) high compared
to the developed world. In this economic evaluation the cost-
effectiveness of interventions (donor management, quality of
testing, administration and additional tests) improving blood
transfusion safety is explored. METHODS: The residual risks of
HIV, HBV and HCV transmission were derived for Angola,
Benin, Botswana, Côte d’Ivoire, Ethiopia, Kenya, Mozambique,
Namibia, Rwanda, Uganda and Zambia from the Global Data-
base on Blood Safety (GDBS; WHO, 2004). Cost-effectiveness
ratios of the scenarios were determined by using a decision tree
combined with a Markov-model. Health gains and costs were
discounted by 3%. RESULTS: The CURRENT (current status)
scenario is cost-saving compared to the NONE (no screening, no
donor management) scenario, averting 2.0 million Disability
Adjusted Life Years (DALYs) and saving US$ 82 million annu-
ally. Over 94,000 new HIV infections are averted and 27,674
and 3360 new HBV and HCV infections respectively. Improving
the blood transfusion services from the CURRENT to the BEST
(100% screening, no errors) scenario shows a cost-effectiveness
ratio of 56.24 US$/DALY averted. With this step 2792 new HIV
infections are averted and 1723 and 1622 new HBV and HCV
infections respectively. In addition to the BEST scenario, HIV
p24 and HCV-antigen testing would avert 19 DALYs at annual
net costs of US$ 1.2 million (63,957 US$/DALY averted).
Extending the BEST scenario with single donation multiplex
NAT averts 60 DALYs at annual net costs of US$ 9.7 million
(161,051 US$/DALY averted). CONCLUSIONS: The current
level of blood transfusion safety provided in the included coun-
tries is cost-saving. However, maximizing the effects of donor
management and screening (coverage and errors) shows a favor-
able cost-effectiveness ratio. Introducing additional tests along-
side antibody testing is associated with high costs and limited
reduction of transmission risks.
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OBJECTIVE: The AIDS Pegasys Ribavirin International Coin-
fection Trial (APRICOT) demonstrated the efﬁcacy and safety of
peginterferon alfa-2a plus ribavirin (RBV) and interferon alfa plus
ribavirin (IFN/RBV) in patients co-infected with HIV-HCV.
However, the cost-effectiveness of treating CHC with peginter-
feron alfa-2a/RBV in this patient population has not assessed from
the Spanish National Health care System (NHS) perspective. The
objective was to establish the clinical prognosis, costs and cost-
effectiveness of peginterferon alfa-2a (180 mcg/week) plus RBV
versus IFN (3 million IU, three times a week) plus RBV, in patients
with HIV-HCV co-infection from a Spanish national health care
system (NHS) perspective. METHODS: A Markov model was
developed to simulate the disease progression of 40-year old
patients with HIV-HCV co-infection. Fibrosis progresión rates
were obtained from published studies. Efﬁcacy, in terms of sus-
tained virological response (SVR), for peginterferon alfa-2a plus
RBV and IFN/RBV in patients with genotype 1, genotypes 2/3
and genotypes 1/2/3 was obtained from APRICOT. Transition
probabilities and quality of life estimates were obtained from pub-
lished literature. Unit costs were obtained from a Spanish data-
base. Cost and outcomes were discounted by 3.5% annually.
RESULTS: In genotype 1 patients, peginterferon alfa-2a plus RBV
compared with IFN/RBV increases patientxs life expectancy by
1.27 years (0.77 quality-adjusted life years (QALYs)), yielding an
incremental cost-effectiveness ratio (ICER) of €3,677/life year
gained (LYG) (€6077/QALY gained). In genotypes 2/3 patients,
peginterferon alfa-2a plus ribavirin increases life expectancy by
4.63 years (2.33 QALYs), yielding an ICER of €569/LYG
(€1130/QALY gained). In genotypes 1/2/3 patients, the ICER is
€1487/LYG (€2762/QALY gained). CONCLUSIONS: From 
the Spanish NHS perspective, peginterferon alfa-2a (40KD)
(PEGASYS®) plus ribavirin (COPEGUS®) in patients with HIV-
HCV co-infection is a cost-effective treatment option, regardless
of HCV genotype.
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Chronic Hepatitis B (CHB) is caused by chronic infection with
Hepatitis B Virus (HBV) and represents a major global health
problem. Traditional CHB treatments are lamivudine (LAM) and
interferon alfa-2a (IFN). Peginterferon alfa-2a (PEG) has been
recently approved for the treatment of CHB disease. OBJEC-
TIVES: To assess the economic and clinical impact of the use of
peginterferon alfa-2a (40KD) versus LAM for the treatment of
HBeAg-negative CHB and versus IFN for the treatment of
HBeAg-positive CHB disease in Italy. METHODS: The CHB
disease course was simulated with the use of a Markov model.
The simulation was prolonged over a cohort’s lifetime. Com-
parative evaluation of PEG vs. LAM was based on a recent phase
III clinical trial in HBeAg-negative CHB. Comparative evalua-
tion of PEG vs. IFN was based on a phase II clinical trial com-
paring the two treatments in HBeAg-positive CHB. Considered
scenarios were: 48-week PEG vs LAM treatment; 48-week PEG
vs 4-year LAM; 24-week PEG vs. IFN. Clinical outcomes mea-
sured were average life years gained (LYs) and quality-adjusted
life years (QALYs). Direct costs were considered and valued
according to current Italian national prices, tariffs and published
literature. Deterministic and probabilistic sensitivity analyses
were performed and acceptability curves generated. Costs and
outcomes were discounted at a 3.5% annual rate. RESULTS:
0.82, 0.68, and 0.26 discounted QALYs per patient are gained
with PEG vs 48-week LAM, 4-year LAM and IFN, respectively.
Discounted incremental costs per patient are €7021, €5725, and
€2304. Corresponding cost-effectiveness and cost-utility ratios
are €9440/LY and €8603/QALY, €9218/LY and €8368/QALY,
